MMI (Medical Microinstruments, Inc.)
7
4
4
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
Role: lead
CONNECT: A Multi-Cohort, Prospective Investigation of the Symani® Surgical System
Role: lead
Clinical Lymphedema Evaluation - Advancing Reconstruction of Head and Neck Lymphatics With Symani
Role: lead
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Role: lead
A Study to Expand the Use of Symani® Surgical System for Peripheral Nerve Repair
Role: lead
PRIMO Post-Market Clinical Follow Up Study
Role: lead
A Global, Prospective, Real-World, Investigation of the Symani® Surgical System for Microsurgical Anastomosis
Role: lead
All 7 trials loaded